On August 31, 2026, Cadrenal Therapeutics announced positive feedback from a July 28 FDA Type D meeting regarding the Phase 3 registrational study protocol for CAD-1005. The FDA aligned on an optimized primary endpoint measuring new or worsening composite thromboembolic events through Day 14 or hospital discharge in Serotonin Release Assay-positive participants. The agency also approved a placebo-controlled design with standard anticoagulation for both arms. Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for critical care cardiology and orphan cardiovascular conditions.

Cadrenal Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company incurred research and development expenses of $0.7 million and general and administrative expenses of $2.6 million, resulting in a net loss of $3.3 million for the quarter ended June 30, 2026. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents, which is expected to fund operations through the first quarter of 2027. The company launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise assets, including CAD-1005, frunexian, and tecarfarin. Additionally, Cadrenal signed an agreement with a global firm to secure non-dilutive funding and completed a private placement generating approximately $3.0 million in gross proceeds, with up to $5.8 million additional potential proceeds if warrants are exercised. The company operates as a late-stage biopharmaceutical firm advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions.

Cadrenal Therapeutics, Inc. announced a strategic realignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise, initiating a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, including CAD-1005, frunexian, and tecarfarin. The company is transitioning to a partnership-driven business model to maximize asset value and commercialization paths. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing specialized therapies for critical care cardiology and orphan cardiovascular conditions.

Cadrenal Therapeutics, Inc. entered into a separation agreement with Chief Medical Officer James J. Ferguson III, who will resign from his position effective July 31, 2026. The agreement includes salary payments through the separation date, COBRA premium coverage for up to six months, and reimbursement of approved business expenses. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with complex medical needs.

James J. Ferguson III will resign as Chief Medical Officer of Cadrenal Therapeutics, Inc. effective July 31, 2026. The company is searching for a replacement and negotiating separation terms. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with complex medical needs.

Cadrenal Therapeutics, Inc. entered into a securities purchase agreement on June 30, 2026, to conduct a private placement with an institutional investor. The company issued pre-funded warrants, Series C-1 warrants, and Series C-2 warrants to purchase a total of 2,880,000 shares of common stock, including placement agent warrants. The combined purchase price for the pre-funded and common warrants was $3.1249 per unit, generating approximately $3.0 million in gross proceeds. The company intends to use the net proceeds for working capital. Directors and officers entered into 60-day lock-up agreements. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders.